Brokerages Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Target Price at $16.56

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.5556.

Several research firms have recently issued reports on IVA. HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Barclays began coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price target for the company.

Hedge Funds Weigh In On Inventiva

Large investors have recently modified their holdings of the business. Creative Planning bought a new position in shares of Inventiva during the second quarter valued at $32,000. Virtu Financial LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva during the fourth quarter worth $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the third quarter worth $116,000. Finally, Cerity Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $93,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $5.37 on Monday. The firm has a 50 day simple moving average of $5.74 and a 200 day simple moving average of $5.34. Inventiva has a one year low of $2.85 and a one year high of $7.98.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million for the quarter. Sell-side analysts forecast that Inventiva will post -0.79 EPS for the current fiscal year.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.